Search research articles
Contact Us
Filters
Showing results (61-70 of 82) with videos related to
Page
of 9
Sort By:
Frontiers in Pharmacology
|
February 5, 2024
Towards a better detection of patients at-risk of linezolid toxicity in clinical practice: a prospective study in three Belgian hospital centers
Hélène Thirot, David Fage, Antonia Leonhardt, et al.
Nature Communications
|
January 19, 2022
Combination of pre-adapted bacteriophage therapy and antibiotics for treatment of fracture-related infection due to pandrug-resistant Klebsiella pneumoniae
Anaïs Eskenazi, Cédric Lood, Julia Wubbolts, et al.
Scientific Reports
|
June 25, 2026
Plasma CXCL13 and fibrosis biomarkers in COVID-19 compared with idiopathic pulmonary fibrosis
Nicolas Gendron, Carla Rial, Clément R Massonnaud, et al.
The Lancet. Infectious Diseases
|
November 26, 2023
Efficacy and safety of rezafungin and caspofungin in candidaemia and invasive candidiasis: pooled data from two prospective randomised controlled trials
George R Thompson, Alex Soriano, Patrick M Honore, et al.
CPT: Pharmacometrics & Systems Pharmacology
|
September 20, 2023
Association between SARS-CoV-2 viral kinetics and clinical score evolution in hospitalized patients
Nadège Néant, Guillaume Lingas, Alexandre Gaymard, et al.
The Journal of Infectious Diseases
|
April 29, 2026
High Nasopharyngeal SARS-CoV-2 Load and Delayed Clearance in Hospitalized Patients With Blood Autoantibodies Neutralizing Type I Interferons
Astrid Marchal, Thibault Kerdiles, Aglaé Perrin, et al.
The Journal of Antimicrobial Chemotherapy
|
March 2, 2022
Effect of remdesivir on viral dynamics in COVID-19 hospitalized patients: a modelling analysis of the randomized, controlled, open-label DisCoVeRy trial
Guillaume Lingas, Nadège Néant, Alexandre Gaymard, et al.
Contemporary Clinical Trials
|
June 11, 2023
Ensuring quality control in a COVID-19 clinical trial during the pandemic: The experience of the Inserm C20-15 DisCoVeRy study
Claire Fougerou-Leurent, Christelle Delmas, Juliette Saillard, et al.
Vaccine
|
February 13, 2023
Immunogenicity of an adjuvanted SARS-CoV-2 trimeric S-protein subunit vaccine (SCB-2019) in SARS-CoV-2-naïve and exposed individuals in a phase 2/3, double-blind, randomized study
Erik Buntinx, Leonardo Brochado, Charissa Borja-Tabora, et al.
Clinical Pharmacokinetics
|
July 30, 2020
Pharmacokinetics/Pharmacodynamics of Antiviral Agents Used to Treat SARS-CoV-2 and Their Potential Interaction with Drugs and Other Supportive Measures: A Comprehensive Review by the PK/PD of Anti-Infectives Study Group of the European Society of Antimicrobial Agents
Markus Zeitlinger, Birgit C P Koch, Roger Bruggemann, et al.
Page
of 9
Search research articles
Search
Showing results (61-70 of 82) with videos related to
Sort By:
Page
of 9
Frontiers in Pharmacology
|
February 5, 2024
Towards a better detection of patients at-risk of linezolid toxicity in clinical practice: a prospective study in three Belgian hospital centers
Hélène Thirot, David Fage, Antonia Leonhardt, et al.
Nature Communications
|
January 19, 2022
Combination of pre-adapted bacteriophage therapy and antibiotics for treatment of fracture-related infection due to pandrug-resistant Klebsiella pneumoniae
Anaïs Eskenazi, Cédric Lood, Julia Wubbolts, et al.
Scientific Reports
|
June 25, 2026
Plasma CXCL13 and fibrosis biomarkers in COVID-19 compared with idiopathic pulmonary fibrosis
Nicolas Gendron, Carla Rial, Clément R Massonnaud, et al.
The Lancet. Infectious Diseases
|
November 26, 2023
Efficacy and safety of rezafungin and caspofungin in candidaemia and invasive candidiasis: pooled data from two prospective randomised controlled trials
George R Thompson, Alex Soriano, Patrick M Honore, et al.
CPT: Pharmacometrics & Systems Pharmacology
|
September 20, 2023
Association between SARS-CoV-2 viral kinetics and clinical score evolution in hospitalized patients
Nadège Néant, Guillaume Lingas, Alexandre Gaymard, et al.
The Journal of Infectious Diseases
|
April 29, 2026
High Nasopharyngeal SARS-CoV-2 Load and Delayed Clearance in Hospitalized Patients With Blood Autoantibodies Neutralizing Type I Interferons
Astrid Marchal, Thibault Kerdiles, Aglaé Perrin, et al.
The Journal of Antimicrobial Chemotherapy
|
March 2, 2022
Effect of remdesivir on viral dynamics in COVID-19 hospitalized patients: a modelling analysis of the randomized, controlled, open-label DisCoVeRy trial
Guillaume Lingas, Nadège Néant, Alexandre Gaymard, et al.
Contemporary Clinical Trials
|
June 11, 2023
Ensuring quality control in a COVID-19 clinical trial during the pandemic: The experience of the Inserm C20-15 DisCoVeRy study
Claire Fougerou-Leurent, Christelle Delmas, Juliette Saillard, et al.
Vaccine
|
February 13, 2023
Immunogenicity of an adjuvanted SARS-CoV-2 trimeric S-protein subunit vaccine (SCB-2019) in SARS-CoV-2-naïve and exposed individuals in a phase 2/3, double-blind, randomized study
Erik Buntinx, Leonardo Brochado, Charissa Borja-Tabora, et al.
Clinical Pharmacokinetics
|
July 30, 2020
Pharmacokinetics/Pharmacodynamics of Antiviral Agents Used to Treat SARS-CoV-2 and Their Potential Interaction with Drugs and Other Supportive Measures: A Comprehensive Review by the PK/PD of Anti-Infectives Study Group of the European Society of Antimicrobial Agents
Markus Zeitlinger, Birgit C P Koch, Roger Bruggemann, et al.
Page
of 9